The product - StablevaX™
Stablepharma’s founder Dr Bruce Roser MB BS, PhD, FRCPA identified and patented the process of using Trehalose to achieve a state of ‘suspended animation’ in a sugar glass to thermally stabilize many vaccines. Trehalose is a naturally occurring sugar with remarkable chemical stability that can stabilise delicate molecules against very hostile environments. This property is observed naturally in some living organisms, most notably in the case of the “resurrection” plant.
Stablepharma does not make or develop vaccines – we take existing WHO approved vaccines, reformulate, and stabilise them, and deliver them in a unique way with our patented process.
Trehalose’s stabilising properties are already used in approximately 25 approved (FDA, EMA) pharmaceuticals worldwide. Stablepharma’s R&D team have identified 60 vaccines suitable for StablevaX™ – we are now using our technology on the current Covid-19 mRNA vaccines.
The StablevaX™ product consists of a pre-filled, pre-dosed syringe containing a precisely dosed, stabilised vaccine inside.
• Sterile water is drawn into syringe prior to injection, this results in the reconstitution of the vaccine regardless of the volume of water drawn.
• Vaccine is then administered.
StablevaX™ has been designed to meet the criteria for usage required by the World Health Organisation (WHO) and its use in the field requires little or no extra training.
Stablepharma does not make or develop new vaccines – we take existing vaccines and stabilise them, using the patented StablevaX™ technology. By housing the pre-dosed and stable vaccine in a syringe, we ensure safe, efficient, and waste-free delivery without the need for the cold chain.
Technology has been tested with positive results
Stablepharma, with its commercial and academic partners, has generated strong in-vitro and in-vivo data for its vaccine programmes including Tetadif (Td) and COVID mRNA. Studies have shown repeatedly that StablevaX™ elicits a strong immune response in animals even after being exposed to high temperatures for long periods of time.
StablevaX™ technology has generated wide range of data including pre-clinical animal challenge potency, ELISA and other analytical assays. If you are interested in learning more about our results, please get in touch: firstname.lastname@example.org.
StablevaX™ patents have been issued in 14 jurisdictions including US, Europe, Japan and several emerging markets.